Search »
- Use quotation marks (e.g., "RSR Manual") to search for exact phrases.
- You must be logged in to search for people in the Ryan White/TargetHIV community.
Content type
Topic Areas
Source
Publication Date
-
-
Ryan White Part A-F Awards Announced for FY21
From the HRSA HIV/AIDS Bureau Update: Special Bulletin - 10/5/21
News Article updated on 10/06/2021 -
Peer Engagement to Improve Linkage to Care and Retention in Care for Women and Youth
University Health uses peers and patient navigators to provide support, reduce barriers, and improve linkage and retention to care for women and youth with HIV. Two peers with lived experience were hired as Outreach Specialists to spearhead the program, encourage medication adherence and use of services, and provide mentoring. The intervention was successful in moderately improving the numbers of clients linked to care, retained in care, and virally suppressed.Resource from the RWHAP Best Practices Compilation updated on 11/14/2023
-
Use of CARES Act Funds and Vaccine Incentives
A new FAQ has been added to the HRSA HIV/AIDS Bureau's Coronavirus Disease 2019 (COVID-19) Frequently Asked Questi
News Article updated on 08/31/2021 -
Hybrid Format for Ryan White 2022
Next year’s Ryan White Conference will adopt an in-person/virtual format, while the Clinica
News Article updated on 10/15/2021 -
Rapid ART: An Essential Strategy for Ending the HIV Epidemic
What HIV care providers can do to create a rapid ART program to get HIV clients on treatment the same day as a diagnosis.Resource updated 09/19/2023
-
Rapid ART Playbook Outlines Steps to Implementation
Guide on implementing rapid ART the administration of antiretroviral therapy (ART) as quickly as possible and ideally on the same day as an HIV diagnosis/clinic visit.Blog updated 03/03/2022
-
TAP-in EHE Webinar Series
Recordings of the TAP-in webinars on topics critical to the Ending the HIV Epidemic Initiative.Resource updated 05/23/2023
-
HRSA Revises RWHAP Policy Notice on Eligibility Determinations
In October 2021, HRSA's HIV/AIDS Bureau revised its client eligibility and recertification policy for the Ryan White HIV/AIDS Program.
News Article updated on 11/02/2021 -
Addressing Substance Use Disorders (SUDs) as a Strategy to End the HIV Epidemic
Review of the impact of SUDs on HIV outcomes and effective evidence-based SUD interventions (Medication Assisted Treatment, Motivational Interviewing, and Contingency Management).Resource updated 03/15/2023
-
RWHAP CARES Act Expenditures Report
How to access the RWHAP CARES Act Expenditures Report and instructions on CARES Act Expenditures Reporting.Resource updated 12/22/2023
-
Use of Social Media and Mobile Technology as Essential Tools for EHE
Strategies to engage hard-to-reach youth and young adults through use of social media and related technologies.Resource updated 03/15/2023
-
Reviewing the RWHAP Program Terms Report/Allocations Report for Project Officers
How to access the Program Terms Report (PTR)/Allocations Report and steps a Project Officer should take in reviewing PTRs and the submission timeline.Resource updated 04/11/2023
-
Ending the HIV Epidemic through Innovations in Rapid ART
Review of innovative Rapid ART strategies in diverse settings.Resource updated 03/15/2023
-
Innovation and Resilience: How Ryan White HIV/AIDS Program Recipients Leverage Telehealth during the COVID-19 Pandemic
Recap of changes made in telehealth laws, regulations, and policies and corresponding efforts of healthcare systems, payers, and providers to modify their services to keep clients with HIV engaged in care provided by HRSA's Ryan White HIV/AIDS Program.Resource updated 06/09/2022
-
New Investigational ART Drugs and Strategies
Review of investigational drugs in phase III trials (as of 2021: Islatravir, Lenacapravir, GSK 3640254/aka GSK “254) and how these investigational agents might be used in treatment in the future. Also, review of long-acting injectables.Resource (Conference Presentation) updated 09/14/2023
-
Managing Polypharmacy and Drug-Drug Interactions
Review of common mechanisms for drug interactions with contemporary ART; therapeutic classes of drugs with high interaction potential with ART; distinctions between oral vs intramuscular cabotegravir/rilpivirin interactions; and comparison of the clinical pharmacology and drug interaction potential of tenofovir alafenamide vs tenofovir disoproxilfumarate.Resource (Conference Presentation) updated 09/14/2023
-
Cases From the Clinic(ians): Antiretroviral Therapy Cases and Panel Discussion
Insights for clinicians on selecting antiretroviral therapy and/or managing patients who: are starting initial therapy; are Elite Controllers; have InSTI-associated weight gain; have persistent low-level viremia; have a discordant CD4+ count response to ART; have ‘Blips’; and/or are aging.Resource (Conference Presentation) updated 04/08/2024
-
Addressing HIV Practitioner and Staff Burnout in the COVID-19 Era
Discussion of recognizing the signs of burnout among clinicians and strategies for self-care.Resource (Conference Presentation) updated 09/14/2023
-
Transgender Women Engagement and Entry to Care (T.W.E.E.T): E2i
T.W.E.E.T. aims to engage transgender women in HIV care by combining weekly peer-based education and discussion groups, leadership training, community building, and the provision of supportive services. Three sites implemented T.W.E.E.T. as part of E2i, an initiative funded by the RWHAP Part F SPNS program from 2017–2021. Clients had improved outcomes across the HIV care continuum 12 months after enrollment in T.W.E.E.T.Resource from the RWHAP Best Practices Compilation updated on 02/09/2024